ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Elfetabart Drozuntecan

Also written as “BNT324” and “DB-1311”.

Its studies are mostly in Small Cell Lung Carcinoma · Prostatic Neoplasms, led by 2 companies.

Drug pageElfetabart Drozuntecan: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTechits history only22 open or runningphase 3since Jan 23, 2026Mar 19, 2025Sep 2028phase 2 · NCT06892548
DualityBio11 open or runningphase 2since Jun 13, 2023Jun 13, 2023Dec 2027phase 2 · NCT05914116

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of DualityBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2023First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT05914116 · 862 planned · United States, Australia, China and more
  2. Jan 29, 2026Named elfetabart drozuntecanINNProposed as its International Nonproprietary Name in WHO's List 134 · before, BNT324, DB-1311

Ahead

  1. Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT05914116

TargetBeta

CD276 →read by rule
“An antibody-drug conjugate (ADC) composed of elfetabart, a humanized monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), that is ”NCIt, by rule

Other programs on CD276

ProgramCompanyFurthest phaseStudies
risvutatug rezetecanHansoh Pharmaceutical Groupphase 330
ifinatamab deruxtecanMerckphase 316
tambotatug pelitecanMediLink Therapeutics (Suzhou)phase 313
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043CSPC Pharmaceutical Groupphase 35
Anti-B7-H3 Antibody-drug Conjugate MHB088CruleMinghui Pharmaceuticalphase 34
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruletj-biopharma-co-ltdphase 33
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01ruleradiopharm-theranostics-ltdphase 21
Autologous Anti-B7-H3 CAR T-cells BCB-276rulebrainchild-bio-incphase 21
Anti-B7-H3/CD28 Bispecific Antibody XmAb808ruleXencorphase 12
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11
HLX316Fosun Pharmaphase 11

Studies

The one study DualityBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05914116Small Cell Lung Carcinoma · United States, Australia, China and more2RecruitingDec 2027862

How it is read

Names in the registry

  • “BNT324”, 2 entries
  • “DB-1311”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.